Stockscreener 앱 받기
1.91
3.24%
0.06
시장 영업 전:
1.87
-0.04
-2.09%
전일 마감가:
$1.85
열려 있는:
$1.84
하루 거래량:
1.12M
Relative Volume:
0.62
시가총액:
$101.50M
수익:
$832.00K
순이익/손실:
$-135.12M
주가수익비율:
-0.3136
EPS:
-6.09
순현금흐름:
$-124.69M
1주 성능:
+17.90%
1개월 성능:
+34.51%
6개월 성능:
-14.73%
1년 성능:
-74.97%
1일 변동 폭
$1.805
$1.93
1주일 범위
$1.75
$2.0793
52주 변동 폭
$1.30
$7.76
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
INO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.91 | 100.97M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow - MSN
Inovio Pharmaceuticals (NASDAQ:INO) Given "Neutral" Rating at HC Wainwright - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Cervical Dysplasia Treatment Market Size Report 2034, - openPR.com
Inovio aims for BLA submission and FDA file acceptance by year-end 2025 as 3107 data shows sustained surgery reduction - MSN
Inovio Pharmaceuticals Inc. Recovery Linked to Earnings Surprise2025 Market Sentiment & Real-Time Buy Signal Alerts - newsyoung.net
Momentum Screeners Rank Inovio Pharmaceuticals Inc. in Top 5 TodayLong Setup & Low Risk Entry Point Guides - newsyoung.net
Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures - AInvest
INOVIO to Announce Q2 2025 Results on August 12 - MSN
INO.O Surges 13.9%: What's Behind Inovio Pharmaceuticals’ Intraday Spike? - AInvest
Inovio Pharmaceuticals shares surge 22.84% intraday after Q2 earnings report, BLA submission plan, and rating upgrade. - AInvest
Inovio Pharmaceuticals (INO) Surges 19.4% on Earnings Optimism—What's Fueling the Biotech Rally? - AInvest
Inovio Pharmaceuticals Soars 12.28% on Q2 Earnings, Clinical Progress - AInvest
Inovio Pharmaceuticals Second Quarter 2025 Earnings: US$0.61 loss per share (vs US$1.19 loss in 2Q 2024) - Yahoo Finance
Inovio rises after promising Q2 results - MSN
Inovio Pharmaceuticals : Second Quarter 2025 Financial Results Conference Call Q2 2025 Financial Results Presentation - MarketScreener
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - The Globe and Mail
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛
Inovio Pharmaceuticals: HC Wainwright Raises PT to $3 from $3, Maintains Neutral Rating. - AInvest
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year - Investing.com
Inovio Pharmaceuticals Q2 2025 Earnings Call Highlights: BLA Submission, Financial Challenges, and Regulatory Progress - AInvest
Inovio Pharmaceuticals Inc. Stock Rallies 14.1%, Outperforms Competitors - 富途牛牛
Inovio Pharmaceuticals shares rise 13.76% intraday after reporting Q2 2025 financial results and progress on INO-3107. - AInvest
Inovio Pharmaceuticals Q2 Results: Net Loss Narrows to $0.61 per Share - AInvest
Inovio rises after promising Q2 results (INO:NASDAQ) - Seeking Alpha
Jefferies Upgrades Inovio Pharmaceuticals(INO.US) to Buy Rating, Cuts Target Price to $1.8 - 富途牛牛
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2025 Earnings Call Transcript - Insider Monkey
Jefferies lowers Inovio stock price target to $1.80 from $2.00 By Investing.com - Investing.com Canada
JMP analyst reiterates Market Outperform rating on Inovio stock By Investing.com - Investing.com Canada
Inovio Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Inovio Pharmaceuticals (INO) Targets BLA Submission for INO-3107 by Year-End 2025 - GuruFocus
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - BioSpace
Inovio’s 2025Q2 Earnings Call: Key Contradictions on Regulatory Strategy, Financial Health, and Clinical Trials - AInvest
Inovio Targets BLA Submission, FDA Approval by Year-End 2025 Amid Positive 3107 Trial Results - AInvest
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Inovio Pharmaceuticals Reports Q2 2025 Financial Progress - TipRanks
Inovio Pharmaceuticals 2025 Q1 Earnings Net Loss Narrows 35.4% - AInvest
Inovio: Q2 Earnings Snapshot - Big Rapids Pioneer
Earnings call transcript: Inovio’s Q2 2025 sees reduced losses, stock rises - Investing.com
Transcript : Inovio Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrow - GuruFocus
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 - Eastern Progress
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | INO Stock News - GuruFocus
Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrowly Beating Estimates - GuruFocus
INOVIO on track to submit BLA for INO-3107 in 2H25, FDA requested rolling submission. - AInvest
INOVIO Reports Second Quarter 2025 Financial Results And Recent Business Highlights - Barchart.com
Major Earnings Expected After the Close Tuesday: CoreWeave, Inovio Pharmaceuticals, Luminar Technologies, and More - AInvest
Options Volatility and Implied Earnings Moves Today, August 12, 2025 - TipRanks
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.55%
0.38%
자본화:
|
볼륨(24시간):